Overview

A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.

Status:
Completed

Trial end date:
2015-04-01

Target enrollment:

Participant gender:

Summary

A phase one study to characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.

Phase:

Phase 1

Details

Lead Sponsor:

Durata Therapeutics Inc., an affiliate of Allergan plc

Treatments:

Dalbavancin
Teicoplanin